2026-04-13T07:57:16Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1077502025-12-06T01:55:39Zcom_2072_1057col_2072_478809col_2072_478917

00925njm 22002777a 4500 dc Darbà, Josep author Ramírez, Gabriela author García-Rivero, Juan L. author Mayoralas, Sagrario author Pascual, José Francisco author Vargas, Diego author Bijedic, Adi author 2017-03-02T15:15:56Z 2017-03-02T15:15:56Z 2017-02 2017-03-02T15:15:56Z The objective of this study was to estimate the economic impact of the introduction of DuoResp® Spiromax®, budesonide/formoterol fixed-dose combination (FDC), focusing on an increase in medication adherence due to an enhancement of the inhalation technique for the treatment of COPD patients in Spain and 5 regions including Andalusia, Catalonia, Galicia, Madrid, and Valencia. ... Administració de medicaments Malalties pulmonars obstructives cròniques Tractament tèrmic Economia de la salut Administration of drugs Chronic obstructive pulmonary diseases Heat treatment Medical economics Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax compared with Turbuhaler in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain